euro adhoc: Sartorius AG / quarterly or semiannual financial statement / Group sales revenue rose 10.2%; currency-adjusted, up 9.1% / EBITDA EBITDA improved 22.8% to EUR31.6 million / EBIT up 31.7% t

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

19.07.2006

During the first half of fiscal 2006, sales revenue of the Sartorius
Group rose 10.2% (currency-adjusted: +9.1%) to EUR257.1 million
(previous year: EUR233.2 mn). In the Biotechnology Division, sales
revenue climbed 12.4% (currency-adjusted: +11.2%) to EUR135.9 million
(EUR120.9 mn); the Mechatronics Division achieved a gain in sales
revenue of 7.9% (currency-adjusted: +6.8%) to EUR121.2 million
(EUR112.3 mn). Up 6.9% (currency-adjusted: +5.6%), order intake also
rose considerably to EUR261.3 million (EUR244.4 mn).

First-half earnings before interest, taxes, depreciation and
amortization (EBITDA) surged 22.8% to EUR31.6 million (EUR25.7 mn).
Earnings before interest and taxes (EBIT) soared 31.7% to EUR22.0
million (EUR16.7 mn); as a result, the EBIT margin increased from
7.2% to 8.6%. For the Biotechnology Division, EBIT rose from EUR9.6
million to EUR14.8 million, whereas for the Mechatronics Division,
EBIT at EUR7.2 million (EUR7.1 mn) was approximately at the previous
year’s level. Second-quarter earnings of the Mechatronics Division
already include an above-average portion of the full-year costs
budgeted for the expansion of company locations in Germany and China
and for the new alignment of the sales organizations of Western
European subsidiaries. Net profit for the period surged 53.3% to
EUR11.7 million (EUR7.6 mn); earnings per share were EUR0.69
(EUR0.45). Despite the rise in capital expenditures, which
approximately doubled compared with the year-earlier figure, net cash
flow at EUR5.0 million (EUR7.2 mn) was positive.

The company is concretizing its goal of increasing full-year sales
revenue by more than 5% and is striving to achieve sales revenue
growth of about 7% on the basis of constant currencies. The target of
achieving earnings before interest and taxes of approximately 10% of
sales revenue is confirmed.

end of announcement euro adhoc 19.07.2006 07:11:31
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com
www.sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Niedersächsische Börse zu Hannover / official dealing